OGT launches new ISCA-endorsed CytoSure™ aCGH arrays for detecting disease and syndrome-related aberrations
Designed in collaboration with the International Standard Cytogenomic Array (ISCA) Consortium to
provide standardised aCGH arrays
Oxford, UK – 02 February 2010. Oxford Gene Technology (OGT), the pioneer of microarraybased
technologies, has introduced three new CytoSure™ ISCA aCGH arrays to meet all
resolution, multiplexing and budget requirements. Designed in collaboration with the International Standard Cytogenomic Array (ISCA) Consortium, the 8 x 60k, 4 x 180k and 4 x 44k CytoSure ISCA formats, provide powerful arrays focusing on disease and syndrome-associated genome regions, in addition to offering whole genome coverage. Using a proprietary 60-mer probe design and multiple rounds of optimisation, the CytoSure ISCA aCGH arrays ensure exceptional reliability and confident detection of genetic aberrations with high signal-to-noise ratios. These features have ensured that the CytoSure ISCA arrays are already used at a number of key facilities, including the Wessex Regional Genetics Laboratory, Salisbury UK where they were evaluated as part of an ongoing multi-platform aCGH comparison being carried out by the National Genetics Reference Laboratory (Wessex).
Each CytoSure array is accompanied with the user-centric CytoSure Interpret analysis software.
This powerful and easy-to-use tool ensures effortless translation of data into meaningful results.
Intuitive features include the “Accelerate” workflow, for customisable automation of routine data
analysis, and full integration with existing data and publicly available cytogenetics databases
including the Database of Genomic Variants (DGV, Canada) and DECIPHER (Sanger Institute,
UK). “OGT has a strong and ongoing commitment to providing cytogeneticists with exceptional
tools for accurate and reliable aberration detection” stated James Clough, OGT’s Vice President
Clinical and Genomic Solutions, “The development of our CytoSure ISCA arrays, in combination
with our advanced CytoSure Interpret analysis software, is a clear example of this. We are
delighted by the level of interest our CytoSure ISCA arrays are generating within the ISCA
consortium around the world”.
In addition to CytoSure ISCA arrays and Interpret software, the CytoSure aCGH product line
includes a range of high quality arrays covering single disorders through to entire syndrome
spreads, as well as SciGene automation instrumentation (now distributed in Europe by OGT). As aresult, OGT’s comprehensive products and services are the ideal solution for running oligo aCGH in the laboratory. For further information on OGT products and services please visit http://www.ogt.co.uk.
Notes for editors:
About Oxford Gene Technology:
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.